The First Objective - AI-Powered Diagnostic for Binocular Vision Disorders
0.5° accuracy eye tracking — 5× more precise than standard. No calibration required. A roadmap to Parkinson's and MS diagnost
Market Demand
The Problem: 55 Million Americans Go Undiagnosed
Over 60 million Americans suffer from Binocular Vision Disorders (BVD) — including Convergence Insufficiency, Vertical Heterophoria, and Lazy Eye — yet fewer than 1 in 10 are ever diagnosed or treated.
In adults, BVDs cause dizziness, nausea, eye strain, and migraines.
In children, they lead to poor school performance and difficulties in sports.
These conditions are highly treatable — but only if accurately diagnosed.
The diagnostic gap is the problem we solve.
Binocular Vision Disorders and other eye movement biomarkers - saccades, fixations and vergence - are emerging as powerful indicators for early detection and continuous monitoring of severe neurological diseases, like Parkinson's disease, Multiple Sclerosis, and many others.
Because you cannot treat what you cannot measure, the treatment development for these diseases is severely impaired by the absence of accessible ways to monitor disease progress and drugs dosage.
Eyecuracy platform creates a foundation for the next generation of neurological diseases diagnostics, monitoring, and treatment development.
Current BVD Diagnostics drawbacks
Current BVD diagnostic procedures are manual, subjective, and require high clinical skill. They are:
- Inaccurate - 2–3 degrees of error, forcing providers to rely on patient self-reports rather than objective measurement, making disease progress monitoring unreliable
- Slow - 20–30 minutes to complete a full test battery, discouraging providers from performing them routinely
- Impossible with telehealth - requiring multiple in-person visits, limiting access for millions of patients
Eyecuracy Solution
A hybrid healthcare platform for BVD diagnostics, monitoring, and treatment.
A simple, affordable device combined with a regulated cloud platform powered by advanced AI algorithms.
Accelerating care and increasing revenue for providers:
- 5× more accurate and reliable than manual — 0.5° vs 2–3° accuracy — streamlining reimbursement and adoption
- Faster diagnostics — over 50% test time cut
- No training overhead — results delivered automatically
- 10% average revenue increase — more patients in less time with higher reimbursement rate
Extending care to the home — continuous monitoring, telehealth, and remote vision therapy support
Validated in the field. Eyecuracy has completed 5 successful pilot studies at UC Berkeley School of Optometry and the University of Regensburg Eye Clinic, holds 8 granted patents across major markets (USA, Europe, China, Japan, Taiwan), and has signed an NRE and Royalties agreement with one of the top 5 neuro-surgery equipment providers globally.